» Articles » PMID: 38928590

Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer's Disease

Overview
Journal Brain Sci
Publisher MDPI
Date 2024 Jun 27
PMID 38928590
Authors
Affiliations
Soon will be listed here.
Abstract

As the population ages worldwide, Alzheimer's disease (AD), the most prevalent kind of neurodegenerative disorder among older people, has become a significant factor affecting quality of life, public health, and economies. However, the exact pathogenesis of Alzheimer's remains elusive, and existing highly recognized pathogenesis includes the amyloid cascade hypothesis, Tau neurofibrillary tangles hypothesis, and neuroinflammation hypothesis. The major diagnoses of Alzheimer's disease include neuroimaging positron emission computed tomography, magnetic resonance imaging, and cerebrospinal fluid molecular diagnosis. The therapy of Alzheimer's disease primarily relies on drugs, and the approved drugs on the market include acetylcholinesterase drugs, glutamate receptor antagonists, and amyloid-β monoclonal antibodies. Still, the existing drugs can only alleviate the symptoms of the disease and cannot completely reverse it. This review aims to summarize existing research results on Alzheimer's disease pathogenesis, diagnosis, and drug therapy, with the objective of facilitating future research in this area.

Citing Articles

Nasal Delivery of Asiatic Acid Ameliorates Scopolamine-Induced Memory Dysfunction in Mice.

Myint S, Rodsiri R, Benya-Aphikul H, Rojanaratha T, Ritthidej G, Islamie R Adv Pharmacol Pharm Sci. 2024; 2024:9941034.

PMID: 39286638 PMC: 11405110. DOI: 10.1155/2024/9941034.

References
1.
Balasundaram A, Srinivasan S, Prasad A, Malik J, Kumar A . Hippocampus Segmentation-Based Alzheimer's Disease Diagnosis and Classification of MRI Images. Arab J Sci Eng. 2023; :1-17. PMC: 9810248. DOI: 10.1007/s13369-022-07538-2. View

2.
Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T . Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015; 18(11):1584-93. PMC: 4694577. DOI: 10.1038/nn.4132. View

3.
Chowdhury S, Chowdhury N . Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. Int J Immunopathol Pharmacol. 2023; 37:3946320231209839. PMC: 10617290. DOI: 10.1177/03946320231209839. View

4.
Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y . Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998; 158(2):134-40. DOI: 10.1016/s0022-510x(98)00122-1. View

5.
Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View